Charles Schwab’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-190,700
| Closed | -$42.1M | – | 3468 |
|
|
2025
Q4 | $42.1M | Buy |
190,700
+45,282
| +31% | +$7.32M | 0.01% | 1267 |
|
|
2025
Q3 | $13.9M | Buy |
145,418
+95,986
| +194% | +$6.13M | ﹤0.01% | 1942 |
|
|
2025
Q2 | $2.41M | Buy |
+49,432
| New | +$1.19M | ﹤0.01% | 2612 |
|
|
2024
Q2 | – | Sell |
-1,341
| Closed | -$24.7K | – | 3636 |
|
|
2024
Q1 | $24.7K | Hold |
1,341
| – | – | ﹤0.01% | 3424 |
|
|
2023
Q4 | $21.3K | Hold |
1,341
| – | – | ﹤0.01% | 3476 |
|
|
2023
Q3 | $25.3K | Hold |
1,341
| – | – | ﹤0.01% | 3487 |
|
|
2023
Q2 | $30.3K | Hold |
1,341
| – | – | ﹤0.01% | 3506 |
|
|
2023
Q1 | $34.1K | Buy |
+1,341
| New | +$38.1K | ﹤0.01% | 3425 |
|
|
2021
Q3 | – | Sell |
-1,250
| Closed | -$51K | – | 3510 |
|
|
2021
Q2 | $51K | Sell |
1,250
-2,503
| -67% | -$106K | ﹤0.01% | 3365 |
|
|
2021
Q1 | $200K | Sell |
3,753
-843
| -18% | -$41.6K | ﹤0.01% | 3322 |
|
|
2020
Q4 | $184K | Hold |
4,596
| – | – | ﹤0.01% | 3267 |
|
|
2020
Q3 | $262K | Hold |
4,596
| – | – | ﹤0.01% | 3082 |
|
|
2020
Q2 | $340K | Buy |
+4,596
| New | +$298K | ﹤0.01% | 2985 |
|
|
2017
Q2 | – | Sell |
-858
| Closed | -$134K | – | 3107 |
|
|
2017
Q1 | $134K | Hold |
858
| – | – | ﹤0.01% | 2982 |
|
|
2016
Q4 | $179K | Hold |
858
| – | – | ﹤0.01% | 2983 |
|
|
2016
Q3 | $197K | Hold |
858
| – | – | ﹤0.01% | 2924 |
|
|
2016
Q2 | $177K | Buy |
+858
| New | +$208K | ﹤0.01% | 2978 |
|
Charles Schwab's CDTX Position: Q1 2026 in Review
Charles Schwab sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 190,700 shares — an estimated $42.1M sold.
Charles Schwab first reported a position in CDTX in Q2 2016 and held it in 17 quarters. The position peaked at $42.1M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Charles Schwab reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Charles Schwab sold 190,700 Cidara Therapeutics shares in Q1 2026, an estimated $42.1M.
- Charles Schwab first reported a position in Cidara Therapeutics in Q2 2016 and held it in 17 quarters.
- Charles Schwab's Cidara Therapeutics position peaked at $42.1M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.